Determination of Blood Tumor Cells

Determination of Blood Tumor Cells Using Magnetic Nanoparticles

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04290923

Enrollment

Registered

2020-03-02

Start date

2017-10-01

Completion date

2022-12-30

Last updated

2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormalities Cell Epithelial, Leukemia, Lymphocytic, Chronic, B-Cell

Keywords

Epithelial Cell Adhesion Molecule, Magnetite Nanoparticles, Tumor cells

Brief summary

Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .

Detailed description

Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood. Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)

Exclusion criteria

Inability to understand the language of the center (German)

Design outcomes

Primary

Measure	Time frame
Number of CTC / lymphocytes removed	1 day

Countries

Switzerland

Outcome results